EG23818A - Sertraline oral concentrate - Google Patents

Sertraline oral concentrate

Info

Publication number
EG23818A
EG23818A EG127599A EG127599A EG23818A EG 23818 A EG23818 A EG 23818A EG 127599 A EG127599 A EG 127599A EG 127599 A EG127599 A EG 127599A EG 23818 A EG23818 A EG 23818A
Authority
EG
Egypt
Prior art keywords
oral concentrate
sertraline oral
sertraline
concentrate
oral
Prior art date
Application number
EG127599A
Other languages
English (en)
Inventor
Nancy J Harper
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG23818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of EG23818A publication Critical patent/EG23818A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG127599A 1998-10-13 1999-10-12 Sertraline oral concentrate EG23818A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
EG23818A true EG23818A (en) 2007-09-19

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
EG127599A EG23818A (en) 1998-10-13 1999-10-12 Sertraline oral concentrate

Country Status (45)

Country Link
EP (1) EP1121107B1 (no)
JP (1) JP3792514B2 (no)
KR (1) KR100417200B1 (no)
CN (1) CN1184962C (no)
AP (1) AP2001002119A0 (no)
AR (1) AR014082A1 (no)
AT (1) ATE254453T1 (no)
AU (1) AU766202B2 (no)
BG (1) BG65085B1 (no)
BR (1) BR9914418A (no)
CA (1) CA2346335C (no)
CO (1) CO5150213A1 (no)
CZ (1) CZ20011286A3 (no)
DE (1) DE69912978T2 (no)
DK (1) DK1121107T3 (no)
DZ (1) DZ2913A1 (no)
EA (1) EA003990B1 (no)
EE (1) EE04868B1 (no)
EG (1) EG23818A (no)
ES (1) ES2209490T3 (no)
GC (1) GC0000175A (no)
GE (1) GEP20032969B (no)
GT (1) GT199900171A (no)
HK (1) HK1040199B (no)
HR (1) HRP20010263B1 (no)
HU (1) HUP0104470A3 (no)
ID (1) ID29845A (no)
IS (1) IS2239B (no)
MA (1) MA26698A1 (no)
MY (1) MY122477A (no)
NO (1) NO20011829L (no)
NZ (1) NZ510756A (no)
OA (1) OA11662A (no)
PA (1) PA8483301A1 (no)
PE (1) PE20001108A1 (no)
PL (1) PL348119A1 (no)
PT (1) PT1121107E (no)
SK (1) SK4582001A3 (no)
TN (1) TNSN99190A1 (no)
TR (1) TR200101090T2 (no)
TW (1) TWI228043B (no)
UA (1) UA72743C2 (no)
WO (1) WO2000021521A2 (no)
YU (1) YU26401A (no)
ZA (1) ZA200102900B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211402B1 (pl) 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (en) 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
WO2005034910A1 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Oral liquid pharmaceutical compositions of sertraline
WO2007052152A2 (en) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Sertraline oral concentrate
US20080268067A1 (en) 2007-03-09 2008-10-30 Llinas Rodolfo R Methods and Compositions for Treating Thalamocortical Dysrhythmia
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
PT768083E (pt) * 1995-07-17 2003-08-29 Pfizer Sertralina para o tratamento de doentes pos-enfarte miocardico
JP3585245B2 (ja) * 1997-07-01 2004-11-04 ファイザー・プロダクツ・インク セルトラリンのゼラチンカプセル封入溶液剤形

Also Published As

Publication number Publication date
DK1121107T3 (da) 2004-02-23
TNSN99190A1 (fr) 2005-11-10
PE20001108A1 (es) 2000-10-26
PA8483301A1 (es) 2000-09-29
CN1184962C (zh) 2005-01-19
CZ20011286A3 (cs) 2001-09-12
AU766202B2 (en) 2003-10-09
CN1323202A (zh) 2001-11-21
SK4582001A3 (en) 2002-02-05
TR200101090T2 (tr) 2001-12-21
HRP20010263B1 (en) 2005-04-30
MA26698A1 (fr) 2004-12-20
WO2000021521A2 (en) 2000-04-20
DE69912978D1 (de) 2003-12-24
ES2209490T3 (es) 2004-06-16
DZ2913A1 (fr) 2004-03-01
AP2001002119A0 (en) 2001-03-22
EE200100221A (et) 2002-08-15
EA003990B1 (ru) 2003-12-25
GC0000175A (en) 2006-03-29
NO20011829D0 (no) 2001-04-10
ZA200102900B (en) 2002-05-29
BG105434A (en) 2001-12-29
OA11662A (en) 2004-12-08
CO5150213A1 (es) 2002-04-29
HRP20010263A2 (en) 2002-06-30
KR100417200B1 (ko) 2004-02-05
UA72743C2 (en) 2005-04-15
GT199900171A (es) 2001-03-28
EP1121107B1 (en) 2003-11-19
JP3792514B2 (ja) 2006-07-05
PT1121107E (pt) 2004-02-27
NO20011829L (no) 2001-06-05
CA2346335A1 (en) 2000-04-20
WO2000021521A3 (en) 2000-07-20
HK1040199B (zh) 2005-05-27
IS5906A (is) 2001-03-23
HUP0104470A3 (en) 2003-12-29
YU26401A (sh) 2005-07-19
HUP0104470A2 (en) 2002-08-28
AU5643699A (en) 2000-05-01
KR20010080096A (ko) 2001-08-22
BG65085B1 (bg) 2007-02-28
JP2002527385A (ja) 2002-08-27
HK1040199A1 (en) 2002-05-31
CA2346335C (en) 2006-04-18
TWI228043B (en) 2005-02-21
NZ510756A (en) 2003-05-30
BR9914418A (pt) 2001-06-26
MY122477A (en) 2006-04-29
EP1121107A2 (en) 2001-08-08
IS2239B (is) 2007-05-15
ID29845A (id) 2001-10-18
ATE254453T1 (de) 2003-12-15
PL348119A1 (en) 2002-05-06
EA200100285A1 (ru) 2001-10-22
EE04868B1 (et) 2007-08-15
DE69912978T2 (de) 2004-04-22
AR014082A1 (es) 2001-01-31
GEP20032969B (en) 2003-05-27

Similar Documents

Publication Publication Date Title
EP1020193A4 (en) ORAL PREPARATION
AU141585S (en) Toothbrush
AU138441S (en) Toothbrush
EP1025776A4 (en) TOOTHBRUSH
SI1121112T1 (en) Stable formoterol concentrate
AU136220S (en) Toothbrush
PL346396A1 (en) Preparation agents
GC0000175A (en) Sertraline oral concentrate
SI1121107T1 (en) Sertraline oral concentrate
GB2336524B (en) Toothbrush
AU137388S (en) Toothpick
GB9820349D0 (en) Oral hygiene system
CA83200S (en) Toothbrush
CA85138S (en) Toothbrush
CA83201S (en) Toothbrush
CA83197S (en) Toothbrush
CA83196S (en) Toothbrush
CA83198S (en) Toothbrush
CA82929S (en) Toothbrush
CA85137S (en) Toothbrush
CA83199S (en) Toothbrush
GB9824876D0 (en) Oral composition
GB9810519D0 (en) Oral composition
AU135842S (en) Bib
GB9820265D0 (en) Bib